checkAd

Biotricity, a Leader in Remote Cardiac Health Monitoring Solutions, Issues Company Roadmap in 2021 Shareholder Letter

The Company believes that it is "well-positioned for 2022."Letter highlights milestones, products roadmap, growth strategy and 2022 goalsREDWOOD CITY, CA / ACCESSWIRE / December 7, 2021 / Biotricity, Inc. (NASDAQ:BTCY) ("Biotricity" or the …

The Company believes that it is "well-positioned for 2022."

Letter highlights milestones, products roadmap, growth strategy and 2022 goals

REDWOOD CITY, CA / ACCESSWIRE / December 7, 2021 / Biotricity, Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a medical diagnostic and consumer healthcare technology company, has released its December 2021 CEO Shareholder Letter, which discusses recent Company milestones achieved including its financial performance, commercialization of its new Biokit, and other state-of-the-art remote cardiac monitoring devices and software apps in development.

Highlights from the shareholder letter include:

  • Recent uplisting to Nasdaq that the Company believes will help further attract a larger pool of sophisticated institutional investors, and a potential increase in liquidity and visibility
  • Commercialization of the personal medical 3-devices kit, Biokit, for integration into the Biotricity ecosystem
  • Record quarterly revenue of $1.81 million for its 2022 fiscal year's second quarter ended September 30, 2021, up 143% year-over-year - its tenth consecutive quarter of triple-digit year-over-year growth
  • The product roadmap for Bioflux®, Biotres, Biocare® Telemed, Biokit, and Bioheart
  • The Company's 2022 goals including launching new state-of-the-art cardiac monitoring solutions and software services.

Dr. Waqaas Al-Siddiq, Founder and CEO of Biotricity commented, "We had a historic second quarter that saw revenue increase 143% YoY, the strengthening of our balance sheet, and uplisting to Nasdaq which has boosted our exposure to investors worldwide. We've made great strides in each vertical we targeted over the year and are well-positioned to continue the execution of our overall growth plan for 2022. We seek to take telemedicine to a new, next-generation level of cost-effectiveness as well as disrupt the cardiac care landscape by reducing patient care costs with improved patient outcomes."

The Biotricity December 2021 Shareholder Letter can be viewed at https://www.biotricity.com/wp-content/uploads/2016/09/Biotricity_Lette ...

About Biotricity Inc.

Biotricity is reforming the healthcare market by bridging the gap in remote monitoring and chronic care management. Doctors and patients trust Biotricity's unparalleled standard for preventive & personal care, including diagnostic and post-diagnostic products for chronic conditions. The Company develops comprehensive remote health monitoring solutions for the medical and consumer markets. To learn more, visit www.biotricity.com.

Seite 1 von 3


Wertpapier



0 Kommentare
Nachrichtenagentur: Accesswire
07.12.2021, 16:35  |  101   |   |   

Schreibe Deinen Kommentar

Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren

 

Disclaimer

Biotricity, a Leader in Remote Cardiac Health Monitoring Solutions, Issues Company Roadmap in 2021 Shareholder Letter The Company believes that it is "well-positioned for 2022."Letter highlights milestones, products roadmap, growth strategy and 2022 goalsREDWOOD CITY, CA / ACCESSWIRE / December 7, 2021 / Biotricity, Inc. (NASDAQ:BTCY) ("Biotricity" or the …

Nachrichten des Autors

Titel
Titel
Titel